View all available purchase options and get full access to this article. The following represents disclosure information provided by the author of this manuscript. All relationships are considered ...
The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...
Especially for therapies, hurdles remain. One is cost. Casgevy, the CRISPR cure for sickle-cell disease and beta-thalassemia, is expensive to make and to buy. Health-care systems in America and ...
Credit: ImmunityBio. Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe ...
Matthew Cobb is professor emeritus at the University of Manchester, UK, and author of The Genetic Age (Profile Books, 2022). On 24 February 1975, some 150 people met at the Asilomar Conference Grounds ...
The global recombinant DNA technology market was worth at approximately USD 803.76 billion in 2023 and is projected to grow USD 1,623.52 billion by 2034 from USD 856.81 billion in 2024, growing at a ...
Newly discovered DNA could shed light on one of Italy's most famous cold cases, finally revealing the "Monster of Florence" serial killer who murdered young couples in the 1970s and 80s. More than ...
Around 2% of the genomes of modern Eurasians contains Neanderthal DNA. Here's how it affects our health. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it ...
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback